Topics

PubMed Journals Articles About "First Drug Approved Treatment Peanut Allergy Children Palforzia" RSS

16:39 EDT 3rd April 2020 | BioPortfolio

First Drug Approved Treatment Peanut Allergy Children Palforzia PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest First Drug Approved Treatment Peanut Allergy Children Palforzia articles that have been published worldwide.

More Information about "First Drug Approved Treatment Peanut Allergy Children Palforzia" on BioPortfolio

We have published hundreds of First Drug Approved Treatment Peanut Allergy Children Palforzia news stories on BioPortfolio along with dozens of First Drug Approved Treatment Peanut Allergy Children Palforzia Clinical Trials and PubMed Articles about First Drug Approved Treatment Peanut Allergy Children Palforzia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of First Drug Approved Treatment Peanut Allergy Children Palforzia Companies in our database. You can also find out about relevant First Drug Approved Treatment Peanut Allergy Children Palforzia Drugs and Medications on this site too.

Showing "First Drug Approved Treatment Peanut Allergy Children Palforzia" PubMed Articles 1–25 of 42,000+

Review Article: Unmet needs of children with peanut allergy: aligning the risks and the evidence.

Peanut allergy is a potentially severe and lifelong allergy, with few effective treatments or preventative measures.


A Single Monoclonal Antibody against the Peanut Allergen Ara h 2 Protects against Systemic and Local Peanut Allergy.

Peanut allergy is the most prevalent and dangerous food allergy. Peanuts consist of a large number of different allergens and peanut-allergic patients are frequently sensitized to multiple allergens. Hence, conventional desensitization approaches aim at targeting as many allergens as possible.

Commercial Claims Costs Related to Healthcare Resource Use Associated With a Diagnosis of Peanut Allergy.

Peanut allergy (PA) affects ∼1.6 million US children. The current standard of care is strict avoidance and prompt reaction treatment. PA healthcare costs and healthcare resource utilization (HCRU) are poorly understood.


3-year follow-up after peanut food challenges: accidental reactions in allergic children and introduction failure in tolerant children.

Forty-one percent of peanut allergic children have allergic reactions and 32% of tolerant children fail to introduce peanut during 3-years after food challenges. Quality of life improved only after successful peanut introduction.

Prevalence and Diagnosis of Sesame Allergy in Children with IgE-Mediated Food Allergy.

Sesame allergy is estimated to affect 17% of children with IgE-mediated food allergy, and often co-occurs with peanut/tree nut sensitization and allergy. Sesame-specific IgE levels may have utility in the clinical management of these patients.

Peanut allergy diagnosis: moving from basic to more elegant testing.

Peanut allergy (PNA) is an IgE-mediated immune disorder which merits particular attention due to its impact on the health and quality of life of millions of patients worldwide. PNA tends to develop in early life and resolves in only 20% of peanut-allergic children. It accounts for the majority of severe food-related allergic reactions. An accurate diagnosis of PNA is vital. In this review we present the approach to the diagnosis of peanut allergy, starting from the history and proceeding to measures of over...

Implementation of Early Peanut Introduction Guidelines: It Takes a Village.

A landmark study showed that early peanut introduction in high-risk infants, defined as infants with moderate to severe atopic dermatitis or egg allergy, reduced the risk of developing peanut allergy. Since this trial, many international societies have updated feeding guidelines to promote early introduction of peanut, usually around 6 months of age. Implementing these guidelines on a national and international level has been challenging. Furthermore, there is confusion if allergy testing is needed before ...

Moving Past "Avoid All Nuts": Individualizing Management of Children with Peanut/Tree Nut Allergies.

It has been common practice to tell patients with allergy to peanut or tree nuts to avoid all nuts. Evidence that unnecessary avoidance of peanuts and eggs is associated with increased risk for developing anaphylaxis to those foods has changed how allergists view previous recommendations to avoid foods that have not caused a reaction. In the absence of evidence, collaborative decision making between clinicians and families should be used to decide whether to avoid tree nuts and how to safely introduce tree ...

Real Life Infant Peanut Allergy Testing in the Post-NIAID Peanut Guideline World.

Dual transcriptomic and epigenomic study of reaction severity in peanut allergic children.

Unexpected allergic reactions to peanut are the most common cause of fatal food-related anaphylaxis. Mechanisms underlying the variable severity of peanut allergic reactions remain unclear.

Specific IgE Decision Point Cutoffs in Children with IgE-Mediated Wheat Allergy and a Review of the Literature.

Wheat IgE-mediated food allergy in children is one of the most frequent food allergies in westernized countries, affecting between 0.4 and 1% of children. Although 95% predictive decision points have been determined for major allergens such as peanut, egg, and milk, the diagnostic performances of wheat-specific IgE (sIgE) and wheat component testing are not well established.

Sustained Successful Peanut Oral Immunotherapy Associated with Low Basophil Activation and Peanut-Specific IgE.

Oral immunotherapy (OIT) can successfully desensitize many peanut allergic subjects, but clinical tolerance diminishes over time upon discontinuation, or low dose maintenance, of peanut. Therefore, in order to improve the efficacy and sustainability of such therapy, we sought to identify biomarkers and clinical tools that can predict therapeutic outcomes and monitor treatment responses.

Can my child with IgE-mediated peanut allergy introduce foods labeled with "may contain traces"?

Peanut IgE-mediated food allergy is one of the most common food allergies in children with a prevalence that has increased in the past decades in westernized countries. Peanut allergies can trigger severe reactions and usually persist over time. Peanut-allergic children and their families are often confronted to processed foods with precautionary allergen labeling (PAL) such as "may contain traces of peanuts", which are frequently used by the food industry. Patients are generally confused as to whether eati...

Update on Early Introduction of Peanut to Prevent Allergy Development: Challenges with Implementation.

This review summarizes the evidence leading towards the development of new guidelines that recommend early introduction of peanut to prevent the development of peanut allergy. It also reviews the current understanding of challenges faced with implementation of these recommendations on a widespread basis.

Identification of the amino-terminal fragment of Ara h 1 as a major target of the IgE-binding activity in the basic peanut protein fraction.

Small, basic peanut proteins are often poorly extracted in pH-neutral buffers that are optimal for the extraction of peanut storage proteins such as Ara h 1. As a result, such proteins are easily missed as potential allergens.

Significantly Increased Threshold Dose After Long-Term Peanut Epicutaneous Immunotherapy and Daily Oral Peanut Intake.

Diagnosis of Ibuprofen Allergy through Oral Challenge.

Ibuprofen is the most commonly used non-steroidal anti-inflammatory drug (NSAID) and is the only NSAID approved for use in infants less than three months of age (1). It is available over-the-counter for the treatment of fever, inflammation and pain, and is often prescribed to treat inflammatory conditions. Over the past decade, there has been a reported shift towards Ibuprofen consumption as an over-the-counter drug, with 70% of ibuprofen being purchased without prescription in 2015, as well as an overall i...

Food allergy immunotherapy: OIT and EPIT.

IgE mediated food allergy remains a significant and growing problem across the globe. Of the various treatment modalities, oral immunotherapy (OIT) and epicutaneous immunotherapy (EPIT) have been the best studied. Across various studies of OIT for egg, milk and peanut allergy, strong levels of desensitization have been shown. With egg and peanut OIT, a limited remission, or sustained unresponsiveness (SU), has further been demonstrated. These advances have been further validated by successful phase 2 and ph...

New Drugs Approved in 2019.

In 2019, the US Food and Drug Administration (FDA) approved 48 novel drugs. Thirty of the 48 (62.5%) novel drug approvals were reviewed and approved through an expedited review pathway while 20 of the 48 (41.7%) were approved for treatment of a rare disease. This review includes a summary of the novel drugs approved by the FDA in 2019.

Visual assessment does not reliably predict peanut content in chocolate covered peanut candies used for oral immunotherapy.

Peanut allergy among Mexican adults with allergic respiratory diseases: prevalence and clinical manifestations.

Peanut allergy among adults with respiratory diseases has seldom been studied within Mexico.

Food and drug allergy, and anaphylaxis in EAACI journals (2018).

The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: "Allergy", "Pediatric Allergy and Immunology (PAI)" and "Clinical and Translational Allergy (CTA)". One of the major goals of EAACI is to support health promotion in which prevention of allergy and asthma plays a critical role and to disseminate the knowledge of allergy to all stakeholders including the EAACI junior members. This paper summarizes the achievements of 2018 in anaphylaxis, food and drug allergy. Main topic...

Determining Levers of Cost-effectiveness for Screening Infants at High Risk for Peanut Sensitization Before Early Peanut Introduction.

Early peanut introduction reduces the risk of developing peanut allergy, especially in high-risk infants. Current US recommendations endorse screening but are not cost-effective relative to other international strategies.

Differences in Management of Peanut Allergy between Allergists and Pediatricians.

The Negative Predictive Value of 5-Day Drug Provocation Test in Nonimmediate Beta-Lactam Allergy in Children.

Extending the drug provocation test(DPT) period is recommended for patients with suspected nonimmediate beta-lactam antibiotic(BLA) allergy and negative DPT. There is no consensus regarding the duration of prolonged provocation.


Quick Search